(VIANEWS) – MFS Government Markets Income Trust (MGF), Western Asset Municipal High Income Fund (MHF), Amgen (AMGN) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio so far. The payout ratio in itself isn’t a promise of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. MFS Government Markets Income Trust (MGF)
1243.35% Payout Ratio
MFS Government Markets Income Trust is a close ended fixed income mutual fund launched and managed by Massachusetts Financial Services Company. The fund invests in the fixed income markets of United States. It primarily invests in investment grade debt instruments. The fund also invests in mortgage backed, U.S. government agencies, international sovereigns, U.S. treasuries, cash and other net assets, emerging markets debt, high grade corporates, and residential mortgage backed securities. It benchmarks the performance of its portfolio against the Barclays U.S. Government/Mortgage Bond Index. MFS Government Markets Income Trust was formed in May 28, 1987 and is domiciled in the United States.
Earnings Per Share
As for profitability, MFS Government Markets Income Trust has a trailing twelve months EPS of $0.02.
PE Ratio
MFS Government Markets Income Trust has a trailing twelve months price to earnings ratio of 154. Meaning, the purchaser of the share is investing $154 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.44%.
Yearly Top and Bottom Value
MFS Government Markets Income Trust’s stock is valued at $3.08 at 08:23 EST, under its 52-week high of $3.34 and above its 52-week low of $2.91.
2. Western Asset Municipal High Income Fund (MHF)
133.67% Payout Ratio
Western Asset Municipal High Income Fund Inc. is a closed ended fixed income mutual fund launched and managed by Legg Mason Partners Fund Advisor, LLC. It is co-managed by Western Asset Management Company. The fund invests in the fixed income markets of the United States. It invests primarily in intermediate and long-term municipal debt securities issued by state and local governments including U.S. territories and possessions, political subdivisions, agencies and public authorities. The fund seeks to invest in investment grade debt securities rated in one of the four highest rating categories by a nationally recognized statistical rating organization to create its portfolio. It benchmarks the performance of its portfolio against the Lehman Brothers Municipal Bond Index. The fund was formerly known as Municipal High Income Fund Inc. Western Asset Municipal High Income Fund Inc. was formed on November 28, 1988 and is domiciled in the United States.
Earnings Per Share
As for profitability, Western Asset Municipal High Income Fund has a trailing twelve months EPS of $0.18.
PE Ratio
Western Asset Municipal High Income Fund has a trailing twelve months price to earnings ratio of 37.78. Meaning, the purchaser of the share is investing $37.78 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.71%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 21, 2024, the estimated forward annual dividend rate is 0.41 and the estimated forward annual dividend yield is 6%.
Yearly Top and Bottom Value
Western Asset Municipal High Income Fund’s stock is valued at $6.80 at 08:23 EST, under its 52-week high of $6.92 and way higher than its 52-week low of $5.92.
Revenue Growth
Year-on-year quarterly revenue growth declined by 5.3%, now sitting on 6.7M for the twelve trailing months.
Volume
Today’s last reported volume for Western Asset Municipal High Income Fund is 39050 which is 33.25% below its average volume of 58503.
3. Amgen (AMGN)
123.43% Payout Ratio
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Earnings Per Share
As for profitability, Amgen has a trailing twelve months EPS of $12.48.
PE Ratio
Amgen has a trailing twelve months price to earnings ratio of 21.42. Meaning, the purchaser of the share is investing $21.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 72.57%.
Yearly Top and Bottom Value
Amgen’s stock is valued at $267.28 at 08:23 EST, way below its 52-week high of $329.72 and way above its 52-week low of $211.71.
Volume
Today’s last reported volume for Amgen is 1865240 which is 36.92% below its average volume of 2957370.
Previous days news about Amgen (AMGN)
- According to CNBC on Monday, 27 May, "The three next largest positions are Zealand Pharma, Amgen and Chugai Pharmaceutical, each of which have a weighting under 5%."
- According to FXStreet on Tuesday, 28 May, "Merck & Co Inc. (MRK) is down -2.7% at $126.00 per share, closely followed by biotech firm Amgen Inc. (AMGN), which shed -7 points, falling -2.33% and dropping below $300.00 per share for the first time since the start of the month. "
4. Pioneer Municipal High Income Advantage Trust (MAV)
104.46% Payout Ratio
Pioneer Municipal High Income Advantage Trust is a closed ended fixed income mutual fund launched and managed by Pioneer Investment Management, Inc. The fund invests in the fixed income markets of the United States. It invests primarily in municipal bonds. The fund benchmarks the performance of its portfolio against the Barclays Capital High Yield Municipal Bond Index and the Barclays Capital Municipal Bond Index. It was formerly known as Pioneer Municipal Advantage Trust. Pioneer Municipal High Income Advantage Trust was formed on August 6, 2003 and is domiciled in the United States.
Earnings Per Share
As for profitability, Pioneer Municipal High Income Advantage Trust has a trailing twelve months EPS of $-0.06.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.39%.
5. Fidus Investment Corporation (FDUS)
86.82% Payout Ratio
Fidus Investment Corporation is a business development company. It specializing in leveraged buyouts, refinancings, change of ownership transactions, recapitalizations, strategic acquisitions, mezzanine, growth capital, business expansion, lower middle market investments, debt investments, subordinated and second lien loans, senior secured and unitranche debt, preferred equity, warrants, subordinated debt, senior subordinated notes, junior secured loans, and unitranche loans. It does not invest in turnarounds or distressed situations. The fund prefers to invest in aerospace and defense, business services, consumer products and services including retail, food, and beverage, healthcare products and services, industrial products and services, information technology services, niche manufacturing, transportation and logistics, and value-added distribution sectors. It seeks to invest in companies based in United States. The fund typically invests between $5 million and $15 million per transaction in companies with annual revenues between $10 million and $150 million and an annual EBITDA between $3 million and $20 million, but it can occasionally invest in larger or smaller companies. It seeks to acquire minority equity stakes and board observation rights in conjunction with its investments.
Earnings Per Share
As for profitability, Fidus Investment Corporation has a trailing twelve months EPS of $2.96.
PE Ratio
Fidus Investment Corporation has a trailing twelve months price to earnings ratio of 6.68. Meaning, the purchaser of the share is investing $6.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.96%.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of $1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 1% and 1%, respectively.
